<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03791801</url>
  </required_header>
  <id_info>
    <org_study_id>2019-4576</org_study_id>
    <nct_id>NCT03791801</nct_id>
  </id_info>
  <brief_title>The Use of Sugammadex in the Critically Ill</brief_title>
  <official_title>Recovery From Optimal Neuromuscular Blockade in the Critically Ill: Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McGill University Health Centre/Research Institute of the McGill University Health Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>McGill University Health Centre/Research Institute of the McGill University Health Centre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Moderate and Deep neuromuscular blockade (rocuronium administered to a train of four count 0
      and post-tetanic count of 1-2) in critically ill patients needing intubation or procedures
      can be reversed immediately and effectively by sugammadex avoiding unnecessary paralysis in
      an already weakened population
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Critically ill is a special population needing immediate and aggressive treatments and
      interventions. Neuromuscular blockade is frequently used to secure an airway, optimize
      ventilation/oxygenation in ARDS, aid in maintaining hypothermia in patients post-cardiac
      arrest. Muscle relaxants can also contribute to neuromuscular weakness in the critically ill
      which can be a devastating condition. Appropriate depth of neuromuscular blockade is
      important but unnecessary paralysis need to be avoided. Rocuronium is one of the most popular
      neuromuscular blockade agents used in the critically ill (1). Sugammadex is a modified
      γ-cyclodextrin that reverses the effect of the steroidal nondepolarizing neuromuscular
      blocking agents rocuronium and vecuronium (2). Sugammadex results in rapid, predictable
      recovery from moderate and deep neuromuscular blockade. Sugammadex has been mostly studied
      and used in the surgical population but its use outside the operating room is still very
      relevant. The investigators set up to evaluate the potential benefit that may result from the
      reversal of NMB with sugammadex compared to neostigmine.

      Objectives

      In critically ill patients undergoing intubation receiving appropriate depth of NMB (moderate
      and deep blockade) the investigators will assess:

      Primary objective:

      1. To determine if choice of reversal agent affects time from intubation to return of a train
      of four (TOF) count of 1, and, separately, to return of a TOF ratio &gt;0.9

      Secondary objectives:

        1. To document the ability of 1.0 mg/kg rocuronium (maximum 100 mg) to achieve satisfactory
           intubation conditions in the ICU, based on measurement of the number of intubation
           attempts and intubation grades in the entire cohort

        2. To document General adverse effects: Hemodynamic instability, need for vasopressors etc
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2019</start_date>
  <completion_date type="Anticipated">July 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>RCT</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Train of four ratio &gt;0.9</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>time from intubation to return of a train of four (TOF) count of 1, and, separately, to return of a TOF ratio &gt;0.9</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Critical Illness</condition>
  <arm_group>
    <arm_group_label>Neostigmine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Will receive rocuronium and neostigmine (5-70microg/kg) + glycopyrrolate (10microg/kg) at train of four 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugammadex</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Will receive rocuronium and sugammadex (4mg/kg) after a successful intubation (ETT is in the trachea and secure).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex</intervention_name>
    <description>the reversal of neuromuscular blockade with sugammadex compared to neostigmine.</description>
    <arm_group_label>Sugammadex</arm_group_label>
    <other_name>Bridion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neostigmine</intervention_name>
    <description>the reversal of neuromuscular blockade with sugammadex compared to neostigmine.</description>
    <arm_group_label>Neostigmine</arm_group_label>
    <other_name>Prostigmin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rocuronium</intervention_name>
    <description>Both groups will receive rocuronium for paralysis during intubation</description>
    <arm_group_label>Neostigmine</arm_group_label>
    <arm_group_label>Sugammadex</arm_group_label>
    <other_name>Zemuron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glycopyrrolate</intervention_name>
    <description>The reversal of neuromuscular blockade with sugammadex compared to neostigmine/glycopyrrolate</description>
    <arm_group_label>Neostigmine</arm_group_label>
    <other_name>Robinul</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients requiring intubation in the intensive care unit

        Exclusion Criteria:

          -  Patients younger than 18 yr, to have known or suspected neuromuscular disease,
             allergies to medications to be used during intubation, a (family) history of malignant
             hyperthermia or severe renal insufficiency (glomerular filtration rate &lt;30 ml/h) will
             not be eligible.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roupen Hatzakorzian, MD MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>McGill University Health Centre/Research Institute of the McGill University Health Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roupen Hatzakorzian, MD MSc</last_name>
    <phone>514 934 1934</phone>
    <phone_ext>31104</phone_ext>
    <email>roupenhatz@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>McGill University Health Center</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roupen Hatzakorzian, MD, MSc</last_name>
      <phone>514 934 1934</phone>
      <phone_ext>34880</phone_ext>
      <email>roupenhatz@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Roupen Hatzakorzian, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MUHC</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>December 18, 2018</study_first_submitted>
  <study_first_submitted_qc>December 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 3, 2019</study_first_posted>
  <last_update_submitted>August 19, 2019</last_update_submitted>
  <last_update_submitted_qc>August 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McGill University Health Centre/Research Institute of the McGill University Health Centre</investigator_affiliation>
    <investigator_full_name>Roupen Hatzakorzian, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>sugammadex</keyword>
  <keyword>rocuronium</keyword>
  <keyword>critically ill</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycopyrrolate</mesh_term>
    <mesh_term>Rocuronium</mesh_term>
    <mesh_term>Neostigmine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

